Monday, December 20, 2010
Inspire Pharmaceuticals Inc., of Durham, N.C., said findings published in the American Journal of Respiratory and Critical Care Medicine showed that cystic fibrosis patients, age 5 and older, receiving inhaled denufosol had better lung exhalation rates than those in the placebo group at the end of 24 weeks in a Phase III trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.